ConferenceAmerican Journal of Gastroenterology · October 1, 2025
Introduction: Anti-CD20 agents confer about a 10% risk of hepatitis B virus (HBV) reactivation in individuals with positive surface antigen (sAg) or core antibody (cAb). AGA guidelines from 2025 recommend sAg and cAb testing prior to therapy initiation. De ...
Full textCite